Will GLP-1 agents ultimately find success in NASH in addition to diabetes and obesity? We explore applications in liver disease in part two of our series.
Will GLP-1RAs ultimately succeed in the marketplace for obesity treatments, where other weight loss drugs have failed? In the first of a two-part blog series, we explore their use as a treatment of Type 2 diabetes & obesity.
Is metformin on the way out as a first-line therapy for type 2 diabetes, to be replaced by tirzepatide? We examine new treatments for diabetes and obesity.